The Gene Therapy Market Is Projected to Be Worth USD 17.3 Billion in 2035, Growing at a CAGR of 18%, During the Period 2022-2035, Claims Roots Analysis

Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development

Roots Analysis has announced the addition of “Gene Therapy Market” report to its list of offerings.

 

Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type I) and Libmeldy™ (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community. Moreover, considering the promising trial results of pipeline candidates, notable players have made investments to support product development and commercialization efforts.

 

To order this 860+ page report, which features 240+ figures and 410+ tables, please visit

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Key Market Insights

 

Over 1,150 gene therapies are currently being developed across different stages

Apart from 11 approved products, most of the aforementioned therapies (70%) are in early stages of development (preclinical / discovery), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of the clinical stage candidates target oncological diseases. Further, majority of such therapies (66%) use adenovirus vectors as molecular carriers.

 

More than 250 companies claim to be engaged in the development of gene therapies, globally

In the past decade, over 160 companies have been established in this domain. Of the total, 60% of the players are small firms. In addition, majority (62%) of these gene therapy developers are based in North America, primarily in the US.

 

290+ clinical trials evaluating gene therapies have been registered, worldwide

Of the total number of trials registered during the period 2015-2020, close to 10% have already been completed, while 56% are presently recruiting patients. Further, presently, around 55% of the trials are evaluating therapy candidates in phase II studies.           

 

USD 8.5+ billion has been invested by both private and public investors, since 2015

The maximum funding amount was raised through secondary offerings (40%), venture capital (28%) and IPOs (16%), during the period 2015-2022. Interestingly, majority (77%) of the funding instances were reported by players based in North America.

 

Over 5,800 patents have been filed / published related to gene therapies, since 2017

Around 90% of the total number of patent applications were related to gene therapies, while the remaining were focused on gene editing-based therapies. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 19%), over the past few years.

 

Merger and acquisition activity in this market has grown at a CAGR of 22%, during 2015-2021

It is worth mentioning that, across most of the instances (43%) both the acquirer and the acquired company were based in North America. Moreover, majority of the acquisitions (26%) were focused on providing access to novel platform / technology, followed by acquisitions undertaken for therapeutic area consolidation (24%) and drug class consolidation (24%).

 

The overall market is anticipated to grow at a CAGR of over 18%, during the period 2022-2035

Gene therapies based on gene augmentationcurrently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. North America (primarily the US) is expected to capture 60% of the market share by 2035, in terms of the sales-based revenues.

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/268/request-sample.html                                                                   

 

Key Questions Answered

Who are the key industry players engaged in the development of gene therapies?
How many gene therapy candidates are currently in the development pipeline? Which key disease indications are targeted by such products?
Which types of vectors are most commonly used for effective delivery of gene therapies?
What are the key regulatory requirements for gene therapy approval, across various geographies?
Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of the development cycle?
What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?
What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
Who are the key CMOs / CDMOs engaged in supplying viral / plasmid vectors for gene therapy development?
What are the key value drivers of the merger and acquisition activity in the gene therapy industry?
Who are the key stakeholders that have actively made investments in the gene therapy domain?
Which are the most active trial sites (in terms of number of clinical studies being conducted) for gene therapies?
How is the current and future market opportunity likely to be distributed across key market segments?

 

 

The financial opportunity within the gene therapy market has been analyzed across the following segments:

Type of Therapy
Gene augmentation
Immunotherapy
Oncolytic viral therapy
Others

 

Type of Gene Delivery Method Used
Ex vivo
In vivo

 

Type of Vector Used
Adeno-associated virus
Adenovirus
Herpes simplex virus
Lentivirus
Non-viral vectors
Retrovirus
Others

 

Target Therapeutic Areas
Cardiovascular diseases
Dermatological diseases
Genetic diseases
Hematological diseases
Infectious diseases
Metabolic diseases
Muscle-related diseases
Oncological diseases
Ophthalmic diseases
Others

 

Route of Administration
Intraarticular
Intracerebral
Intracoronary
Intradermal
Intralesional
Intramuscular
Intrapleural
Intrathecal
Intratumoral
Intravenous
Intravesical
Intravitreal
Subretinal
Topical
Others

 

Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World

 

The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration and recent developments (if available).

Abeona Therapeutics
AGTC
AnGes
Biogen
BioMarin Pharmaceutical
bluebird bio
Castle Creek Biosciences
CG Oncology
FerGene
GenSight Biologics
Helixmith
Holostem Terapie Avanzate
Inovio Pharmaceuticals
Kolon TissueGene
Krystal Biotech
Lysogene
Neurophth Therapeutics
Orchard Therapeutics
Pfizer
PTC Therapeutics
REGENXBIO
Sangamo Therapeutics
Spark Therapeutics
VBL Therapeutics

 

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

Investor Series: Opportunities in the Cell and Gene Therapy Market
Gene Editing beyond CRISPR Market
Cell and Gene Therapy Bioassay Services Market

Media Contact
Company Name: Roots Analysis
Contact Person: Gaurav Chaudhary
Email: Send Email
Phone: +1 (415) 800 3415, +44 (122) 391 1091
City: London
Country: United Kingdom
Website: https://www.rootsanalysis.com/

Are you a market researcher?

Explore our research partnership options.

Partnerships

Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: